Top 5 Takeaways Racial and ethnic disparities in influenza hospitalizations and vaccination coverage have persisted in the U.S. from 2009–10 through 2021–22, with Black, American Indian/Alaska Native (AI/AN), and Hispanic

Top 5 Takeaways Influenza A(H3N2) virus, specifically clade 3C.2a1b.2a.2, emerged in Chile much earlier than in pre-pandemic seasons, resulting in 1,002 hospitalizations in 2022. The influenza vaccination was found to

Top 5 Takeaways New and Updated Vaccine Recommendations: The 2024 immunization schedule includes key changes, notably for influenza, pneumococcal vaccines, RSV monoclonal antibody (RSV-mAb), respiratory syncytial virus vaccines (RSV), COVID-19

Top 5 Takeaways New and Updated Vaccine Recommendations: The 2024 schedule includes changes for respiratory syncytial virus (RSV), influenza, COVID-19, inactivated poliovirus vaccine (IPV), Mpox vaccine, and meningococcal vaccines. Removal

Top 5 Takeaways Bivalent mRNA COVID-19 Vaccine Effectiveness: The bivalent mRNA COVID-19 vaccine was found to be 47% effective in preventing thromboembolic events in immunocompetent persons aged ≥65 years and

Top 5 Takeaways Low Vaccination Rates Among Young Children: As of July 2022, only 4% of children aged 6 months–4 years had received at least one dose of the COVID-19

Top 5 Takeaways Bivalent Boosters’ Effectiveness: The study reveals that bivalent mRNA COVID-19 boosters offer significant additional protection against symptomatic SARS-CoV-2 infection, especially for those who had 2 to 4

Top 5 Takeaways: Bivalent mRNA Vaccine Effectiveness: The study found that bivalent mRNA vaccines are effective in preventing COVID-19–associated emergency department/urgent care encounters and hospitalizations among immunocompetent adults. Comparative Analysis:

Top 5 Takeaways: One-Dose JYNNEOS Vaccine Efficacy: One dose of JYNNEOS vaccine, administered ≥14 days before illness onset, demonstrated some protective effects against mpox, including reduced symptoms and lower hospitalization